Neal Mody

Acumino is an R&D company that has a breakthrough platform and method for training and testing robots to execute high functioning tasks in homes and businesses- at near human level performance. We have solved one of the most intractable challenges facing robotics: grasping and manipulation in dynamic and highly diverse environments including around people.

HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies.

Probius, is a deep-tech company bridging the data gap between biology and AI, thereby illuminating new opportunities for the way biomedical research and healthcare are practiced. By combining physics, mathematics, and biological data, the company will usher in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D, with over $15M of financial support from the DoD and early-stage investors, the company is commencing the commercialization of its revolutionary products

Juno Diagnostics supports growing families and their providers through every step of the pregnancy journey. Our expert team of scientists is developing the next generation of accessible and affordable prenatal screening assays based on cell-free DNA to empower families with science from the start. *COMMERCIAL OPERATIONS PERMANENTLY CLOSED*

Optina’s Retinal Deep Phenotyping platform addresses the major challenges faced by the healthcare system related to an aging population.   Recently, Optina was granted breakthrough device designation by the FDA for our first indication in Alzheimer’s Disease detection which enables a dramatic improvement in the diagnostic accuracy of dementia.   Our ecosystem comprised of a proprietary platform and a network of eye clinics creates a new and efficient means for simple patient stratification. The ecosystem allows for the collection of data rich retinal images with 30X more information than current retinal imaging platforms.   Algorithm development utilizes a ground truth that is based on specifically characterized patients from leading institutions around the world.   With our developing product pipeline, Optina continues to bring clarity and accessibility to early stage diagnosis, improving the life of millions.

Pronounced Me – M – D, we're simplifying how people access healthcare. MeMD® provides high-quality, convenient and affordable healthcare on-demand. Using our proprietary technology, we connect patients seeking care for minor medical issues or behavioral health concerns with licensed medical providers and therapists, who conduct video-based visits privately and securely online, over the phone, or via mobile app. Our business solutions are customizable, easy to implement, and reduce administration time and costs. They serve as a natural complement to an existing health plan, enabling employers to become healthcare champions to their employees while improving productivity and decreasing absenteeism. And in a world of exponentially increasing healthcare costs, we provide the best value without sacrificing quality across the care delivery spectrum, from the patient experience to program administration. We help your team stay focused, present and productive with convenient, anytime access to medical care and therapy.

We are a community of tech philanthropists who believe that we can change the physical world by creating virtual ones. Where technology is not only an entertainment tool but also our greatest resource to connect humanity. Mobile game focused, we believe that your game play should be purposed for real world progress. Play with us and watch what you love transform lives globally.

Based in Waterloo, Ontario and Scottsdale, Arizona, Ambature, Inc. is the world leader in a-axis high-temperature superconducting technology. We design superconducting materials and quantum devices to power an innovative, sustainable future. Nearly half of Ambature’s intellectual property portfolio is dedicated to computing and sensing, while the other half is dedicated to clean energy—the generation, transmission and storage of electricity. Our unique materials and scalable device architectures enable two important shifts in the advanced chips industry: mass production and higher operating temperatures of superconducting devices. If the transistor is the most fundamental semiconductor device, then the Josephson junction (JJ) is the most fundamental superconductor device. JJs are building blocks for sensors, quantum computers, and high-performance or energy-efficient classical computers. Our JJs can be manufactured at scale in any major foundry in the world using standard silicon fabrication equipment. Semiconductors conduct electricity with some resistance. Resistance generates heat in wires, batteries, antennas, smartphones, computers, etc. Heat is the major barrier to advancements in semiconductor power, speed, density, efficiency, and reliability. Our materials address the heat problem because superconductors conduct electricity without resistance. Superconductors typically operate at very cold temperatures, but Ambature’s roots are in research towards room temperature superconductivity. There are low-temperature superconductors (LTS) and high-temperature superconductors (HTS). HTS devices reduce cooling power consumption and coolant costs by an order of magnitude. Ambature’s a-axis HTS JJs will be the first commercially available, mass produced HTS tunnel junctions. They are viable because we have overcome historical technological barriers by mastering a-axis rather than conventional c-axis epitaxial growth.

Acumino is an R&D company that has a breakthrough platform and method for training and testing robots to execute high functioning tasks in homes and businesses- at near human level performance. We have solved one of the most intractable challenges facing robotics: grasping and manipulation in dynamic and highly diverse environments including around people.

HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies.

Probius, is a deep-tech company bridging the data gap between biology and AI, thereby illuminating new opportunities for the way biomedical research and healthcare are practiced. By combining physics, mathematics, and biological data, the company will usher in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D, with over $15M of financial support from the DoD and early-stage investors, the company is commencing the commercialization of its revolutionary products

The Endless Frontier Labs (EFL) is a nine-month, goal-oriented mentorship program at NYU Stern School of Business designed for early-stage science and technology startups worldwide (no NYU affiliation required). EFL helps transform breakthrough scientific and technological innovations into high-impact businesses. Participating startups receive mentorship from an elite network of successful entrepreneurs, business leaders, investors, and scientists, drawn from New York and beyond. EFL is a unique, “founders first” program and does not charge fees or take equity in startups, and participating startups are drawn from all over the world.

Juno Diagnostics supports growing families and their providers through every step of the pregnancy journey. Our expert team of scientists is developing the next generation of accessible and affordable prenatal screening assays based on cell-free DNA to empower families with science from the start. *COMMERCIAL OPERATIONS PERMANENTLY CLOSED*